🇺🇸 ABP 501 in United States

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDA authorised ABP 501 on 23 September 2016

Marketing authorisation

FDA — authorised 23 September 2016

Application: BLA761024
Marketing authorisation holder: AMGEN INC
Local brand name: AMJEVITA
Indication: INJECTABLE — INJECTION
Status: approved

Read official source →

Other Immunology / Rheumatology approved in United States

Frequently asked questions

Is ABP 501 approved in United States?

Yes. FDA authorised it on 23 September 2016.

Who is the marketing authorisation holder for ABP 501 in United States?

AMGEN INC holds the US marketing authorisation.